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Abstract
 
Epstein-Barr virus (EBV)–encoded nuclear antigen (EBNA)1 is thought to escape cytotoxic T
lymphocyte (CTL) recognition through either self-inhibition of synthesis or by blockade of
proteasomal degradation by the glycine-alanine repeat (GAr) domain. Here we show that
EBNA1 has a remarkably varied cell type–dependent stability. However, these different deg-
radation rates do not correspond to the level of major histocompatibility complex class
I–restricted presentation of EBNA1 epitopes. In spite of the highly stable expression of
EBNA1 in B cells, CTL epitopes derived from this protein are efficiently processed and pre-
sented to CD8
 
  
 
T cells. Furthermore, we show that EBV-infected B cells can readily activate
EBNA1-specific memory T cell responses from healthy virus carriers. Functional assays re-
vealed that processing of these EBNA1 epitopes is proteasome and transporter associated with an-
tigen processing dependent. We also show that the endogenous presentation of these epitopes is
dependent on the newly synthesized protein rather than the long-lived stable EBNA1. Based on
these observations, we propose that defective ribosomal products, not the full-length antigen, are
the primary source of endogenously processed CD8
 
  
 
T cell epitopes from EBNA1.
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Introduction
 
The interaction of CTLs with the MHC–peptide complex
is a critical step toward the initiation and propagation of
specific immune responses against viral infection (1). The
specificity of this interaction is determined by two distinct
components, namely, MHC-restricted presentation of a
peptide epitope, and a heterodimeric 
 
   
 
cell surface pro-
tein called the TCR (2). It is now well recognized that a
successful latent infection by herpes viruses such as EBV is
dependent on various strategies to evade this potent antivi-
ral CTL response in the immune-competent host (3).
These escape mechanisms include limited gene expression
during latent infection, virus replication in immune-privi-
leged tissues, down-regulation of MHC and adhesion mol-
ecules, and sequence variation affecting peptide binding to
MHC molecules or recognition by the TCR of CTLs (4).
Previous studies have shown that the latent growth-
transforming infection by EBV elicits a strong CD8
 
  
 
CTL
response directed against all the nuclear antigens except
EBV-encoded nuclear antigen (EBNA)1 (5). These obser-
vations were consistent with other studies that showed that
mammary carcinoma cells transfected with EBNA1 are
poorly immunogenic in mice, whereas strong immunoge-
nicity was induced by expression of other EBV proteins
that are highly immunogenic in humans, suggesting that
CTL evasion occurs across species (6, 7). The failure of
EBNA1-specific T cells to recognize EBV-infected B cells
has been attributed to an internal glycine-alanine repeat
(GAr) domain of EBNA1 that acts as a cis inhibitor of
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MHC class I–restricted presentation (8). It was proposed
that the GAr sequence within EBNA1 forms 
 
  
 
sheets that
are resistant to unfolding and affect its capacity to associate
with various components of the ubiquitin(Ub)/proteasome
pathway, including Ub conjugation enzymes and/or regu-
latory subunits of the proteasome (9, 10). However, previ-
ous studies from our laboratory demonstrated that protea-
somal targeting in conjunction with the 
 
N
 
-end rule can
override the GAr-mediated inhibitory effect and allow en-
dogenous processing of EBNA1 through the MHC class
I pathway (11). More recently, Yin et al. (12) showed
that the GAr domain also inhibits mRNA translation of
EBNA1 in cis and thus argued that low antigen expression
in virus-infected cells, rather than proteasomal blockage, is
the primary mechanism preventing antigen presentation on
MHC class I molecules.
However, neither of these models are able to explain the
mechanisms by which occasional ex vivo EBNA1-specific
T cell responses can be detected in EBV-infected individu-
als (13). Blake et al. (14) proposed that these EBNA1-spe-
cific responses might be generated by the cross-presenta-
tion of EBNA1 protein through the exogenous pathway,
which is not affected by the GAr sequence. Alternatively,
the GAr sequence is unlikely to prevent presentation of
peptides from EBNA1 that are derived from defective ribo-
somal products (DRiPs) that are estimated to contribute up
to 30% of newly synthesized mRNA (15–17). To explore
this possibility and further delineate the mechanisms by
which the EBNA1-specific T cell responses are generated,
we conducted an extensive analysis of EBNA1 expression
in different cell types and compared endogenous presenta-
tion of CTL epitopes in these cells. Here we report that
EBV-infected cells can directly present EBNA1 epitopes to
T cells and this presentation proceeds through a pathway in
which endogenous processing of CTL epitopes is not de-
pendent on the degradation of full-length antigen.
 
Materials and Methods
 
Cell Lines.
 
All cell lines were routinely maintained in RPMI
1640 supplemented with 2 mM 
 
l
 
-glutamine, 100 IU/ml penicil-
lin, and 100 
 
 
 
g/ml streptomycin plus 10% FCS (referred to as
growth medium), unless otherwise stated. EBV-transformed lym-
phoblastoid cell lines (LCLs) were established from healthy sero-
positive donors by exogenous virus transformation of peripheral
B cells using the B95.8 virus isolate as previously described (18).
HLA class I–deficient LCLs (C1R; reference 19) transfected with
HLA B
 
*
 
0801 (C1R.B8) and C1R.B8 cells transfected with
HSV-1–encoded transporter associated with antigen processing
(TAP) inhibitor, ICP47 (C1R.B8.ICP47; provided by J. Mc-
Cluskey, University of Melbourne, Melbourne, Australia), were
also used in this work. These C1R.B8 transfectants were main-
tained in growth medium supplemented with 500 
 
 
 
g/ml Geneti-
cin (Invitrogen), whereas growth medium for C1R.B8.ICP47
was supplemented with 500 
 
 
 
g/ml Geneticin and 4 
 
 
 
g/ml
Puromycin (Sigma-Aldrich). In addition, HLA class I–deficient
721.221 LCLs (referred to as 0.221; reference 20) and 0.221
LCLs transfected with HLA B
 
*
 
3501 (0.221.B35) were also used
in this work. Three different human primary epithelial cell lines
(SVMR6, HaCaT, and HEK 293; references 11, 21, and 22)
were used for EBNA1 half-life analysis or CTL assays (see
below).
 
Inhibitors.
 
Brefeldin A (BFA) and chloroquine were pur-
chased from Sigma-Aldrich. The protease inhibitors, leupeptin
and pepstatin, were from Boehringer. The proteasome inhibitors,
lactacystin and Cbz-L3, were provided by E. Wiertz (Leiden
University, Leiden, Netherlands).
 
Expression Constructs.
 
Full-length EBNA1 was cloned into
the expression vector pcDNA3.1 (Invitrogen) to generate the ex-
pression construct EBNA1 (11). In addition, a modified EBNA1
construct in which the (GAr) domain was deleted was generated
to give EBNA1
 
 
 
GA (11). The above constructs included in-
sertion of a well-defined, HLA-B8–restricted EBNA-3 CTL
epitope, FLRGRAYGL (referred to as FLR; reference 23), into
the SacII site at nucleotide position 1853 of EBNA1, to allow as-
sessment of endogenous processing of EBNA1 by FLR-specific
CTL clones (see Fig. 1 A). To assess expression of EBNA1 and
EBNA1
 
 
 
GA, the inserts from the above pcDNA3.1 constructs
were subcloned in frame with a sequence coding for green fluo-
rescent protein (GFP; pEGFP-N1; CLONTECH Laboratories,
Inc.): EBNA1-GFP and EBNA1
 
 
 
GA-GFP.
 
Construction of Recombinant Ad5F35-EBNA1 Adenovirus.
 
The
assembly and production of recombinant Ad5F35-based adeno-
viruses was completed in three stages using a highly efficient, li-
gation-based protocol of Adeno-X System (CLONTECH
Laboratories, Inc.; reference 24). First, full-length EBNA1 and
EBNA1
 
 
 
GA in pcDNA3.1 were digested with restriction en-
zymes NheI and XbaI, and subcloned into the pShuttle expres-
sion vector to create EBNA1-pShuttle and EBNA1
 
 
 
GA-pShut-
tle. Second, after amplification in 
 
Escherichia coli
 
, the expression
cassettes from both pShuttle vectors were excised and ligated into
an Ad5F35 expression vector. Finally, the recombinant Ad5F35-
EBNA1 and Ad5F35 EBNA1
 
 
 
GA vectors were transfected into
HEK 293 cells, and recombinant adenoviruses were harvested
from transfected cells by freeze thawing.
 
Transfection of EBNA1 Expression Constructs.
 
DG75 cells
were grown to log phase. 5 
 
  
 
10
 
6 
 
cells were transfected in
RPMI1640/10% FCS growth medium with 10 
 
 
 
g of expression
constructs EBNA1-GFP, EBNA1
 
 
 
GA-GFP, or the GFP vector
control using the BioRad Gene Pulser (960 
 
 
 
F, 250 V, 0.4 cm
gap electrode, 300 
 
 
 
l assay volume, 25
 
 
 
C; reference 11). For the
adherent cell lines (HaCaT, SVMR6, or HEK293), 5 
 
  
 
10
 
5 
 
cells
were seeded into T25 flasks. At 60–80% confluency, the cells
were transfected with 1 
 
 
 
g EBNA1-GFP, EBNA1
 
 
 
GA-GFP, or
the GFP vector control using Effectene (QIAGEN) according to
the manufacturer’s instructions.
 
Degradation of EBNA1 Proteins.
 
All EBNA1 degradation
studies were performed as previously described (11). In brief, at
36 h after transfection, 50 
 
 
 
g/ml cycloheximide (Sigma-Aldrich)
was added to 8 
 
  
 
10
 
6 
 
cells. Equal aliquots of cells were removed
at time points 0 min, 4, 8, 24, and 30 h, lysed in SDS-PAGE
sample dye, and resolved under reducing conditions on a 7.5%
SDS polyacrylamide gel. For adherent cells, transfectants were
harvested by scraping and processed as described for suspension
cells. The proteasome inhibitor, lactacystin, was added to the cells
at a final concentration of 10 
 
 
 
g/ml at 24 h after transfection.
 
Detection of EBNA1 by Immunoblotting.
 
After gel electro-
phoresis, proteins were transferred to a nitrocellulose membrane
(Hybond-C; Amersham Biosciences) and blocked in 5% milk
powder/0.5% Tween/PBS. To detect GFP fusion proteins,
membranes were probed with a GFP antibody (Molecular
Probes) at 1:2,000, followed by a polyclonal sheep anti–rabbit 
Tellam et al. 
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horseradish peroxidase–conjugated antibody. Protein bands were
detected using Chemiluminescence Reagent Plus (PerkinElmer).
Protein levels were compared by densitometric analysis using Im-
agequant software (Molecular Dynamics). To determine the
ubiquitination status of EBNA1 and EBNA1
 
 
 
GA, 5 
 
  
 
10
 
5
 
SVMR6 and HeLa cells were cotransfected with expression
vectors encoding 0.8 
 
 
 
g hemagglutinin (HA)-tagged 8XUb
(pMT123; provided by M. Treier, University of California San
Diego, San Diego, CA) and 0.6 
 
 
 
g EBNA1-GFP, EBNA1
 
 
 
GA-
GFP, or latent membrane protein 1 (LMP1)-GFP. 36 h after
transfection, the cells were lysed and any resulting Ub-EBNA1 or
Ub-LMP1 complexes were immunoprecipitated with an anti-
HA–specific mAb (Roche Diagnostics). These complexes were
resolved by SDS-PAGE followed by immunoblotting with an
anti-GFP antibody.
 
CTL Cultures.
 
CTL clones were generated by agar cloning as
follows: 2 
 
  
 
10
 
6 
 
PBMCs from HLA B
 
*
 
3501
 
  
 
EBV-exposed indi-
viduals were stimulated in 2 ml growth medium with autologous
PBMCs that had been precoated with the EBNA1 epitope,
HPVGEADYFEY (referred to as HPV; 1 
 
 
 
M for 1 h, re-
sponder/stimulator ratio of 2:1). After 3 d, cells were dispersed
and seeded in 0.35% agarose (Seaplaque; BioWhittaker Molecular
Applications) containing RPMI 1640, 20% FCS, 25% superna-
tant from MLA-144 cultures, and 50 U/ml rIL-2. Colonies were
harvested after an additional 3–5 d and amplified in culture with
biweekly restimulation with rIL-2, supernatant from the Gibbon
lymphosarcoma T cell line, MLA-144 (86102901; European
Collection of Cell Cultures) as a source of T cell growth factor,
and the 
 
 
 
-irradiated (8,000 rads) autologous LCLs.
Short-term CTL bulk cultures were used as effectors in cyto-
toxicity assays. These were generated by culturing PBMCs (2 
 
 
 
10
 
6 
 
per 2-ml well) in growth medium with 
 
 
 
-irradiated (8,000
rads) LCLs (responder/stimulator ratio of 20:1). LCL-stimulated
CTL cultures were split and restimulated with additional irradi-
ated autologous LCLs on day 7. The CTL bulk cultures were
used in chromium release assays on day 10.
 
In Vitro Inhibition Studies.
 
SVMR6 keratinocytes or LCLs
were pretreated with either class I inhibitors, 10 
 
 
 
g/ml lactacys-
tin, 1 
 
 
 
g/ml BFA, and 10 
 
 
 
g/ml Cbz-L3, or class II inhibitors,
80 
 
 
 
M chloroquine, 100 
 
 
 
M leupeptin, and 50 
 
 
 
M pepstatin for
45 min. The cells were then infected with a recombinant adeno-
virus expressing full-length EBNA1. At 18 h after infection, the
cells were used as targets in a standard 
 
51
 
Cr-release assay. Inhibi-
tors were kept at the above concentrations during the 5-h assay
except for chloroquine, which was lowered to a final concentra-
tion of 20 
 
 
 
M. The FLRGRAYGL-specific CTL clone, LC13,
was used to assess CTL activity of EBNA1 with the inserted HLA
B8–restricted epitope.
 
Intracellular Cytokine Staining.
 
PBMCs from HLA B35
 
  
 
indi-
viduals were incubated overnight for 14–16 h at 37
 
 
 
C in growth
medium supplemented with 20 U/ml recombinant IL-2 with
and without the following cell types at a 20:1 ratio: autologous
LCLs, 721.221, 7221.221.B35, and allogeneic LCL. GolgiPlug™
(BD Biosciences) was added to the samples according to the man-
ufacturer’s instructions during the second hour of incubation. Af-
ter the incubation, cells were washed and resuspended in staining
buffer consisting of Dulbecco’s PBS with GolgiPlug™ and 1%
FCS. Cells were then stained with PE-conjugated HPV-B
 
*
 
3501
tetramer (ProImmune) and Tricolor-conjugated anti-CD8 (Cal-
tag) for 30 min at 4
 
 
 
C in the dark. The cells were then fixed for
20 min at 4
 
 
 
C with Cytofix/Cytoperm™ (BD Biosciences) and
resuspended in Perm/Wash™ permeabilization buffer (BD Bio-
sciences) according to the manufacturer’s protocol. The cells
were then stained with FITC-conjugated anti–human IFN-
 
 
 
(BD Biosciences) for 30 min at 4
 
 
 
C in the dark. Cells were
washed in permeabilization buffer and resuspended in staining
buffer before analysis by three-color flow cytometry on a Becton
Dickinson FACSCalibur™ cytometer.
 
Cell Surface MHC–Peptide Stripping and Antigen Presentation As-
says.
 
For MHC–peptide stripping, HLA B35
 
  
 
LCLs were
washed in PBS and pellets were resuspended in a citrate buffer
phosphate, pH 3, (0.131 M citric acid, 0.066 M Na
 
2
 
HPO
 
4
 
) for 2
min on ice. The suspension was then neutralized by a 100-fold
dilution with RPMI/10% FCS, and cells washed twice. Aliquots
of cells were resuspended in 2 ml complete medium and incu-
bated in the presence or absence of 50 
 
 
 
M cycloheximide for
5 h. To assess the surface MHC class I expression, these LCLs were
preincubated with anti–MHC class I mAb (W6/32; American
Type Culture Collection) followed by incubation with FITC-
labeled anti–mouse Ig. The fluorescence intensity was measured
by FACSCalibur™ and data were analyzed by CELLQuest™
software (Becton Dickinson). PBMCs from HLA B35
 
  
 
individu-
als were incubated overnight for 14–16 h at 37
 
 
 
C in growth me-
dium supplemented with 20 U/ml recombinant IL-2 with and
without the stimulator cells at a responder/stimulator ratio of
20:1. These stimulator cells included autologous LCLs, the citrate
buffer–treated HLA B35
 
  
 
LCLs after incubation in the absence or
presence of cycloheximide and the untreated HLA B35
 
  
 
control
LCL after cycloheximide treatment. The responding cells were
assessed for intracellular IFN-
 
  
 
expression as described above.
 
In Vitro Cytotoxicity Assays.
 
EBV-specific CTL clones or
polyclonal T cell lines were used as effectors in the CTL assays. In
some experiments, target cells were transfected with EBNA1 ex-
pression vectors EBNA1-GFP or EBNA1
 
 
 
GA-GFP for 36 h or
infected with recombinant adenovirus encoding EBNA1 or
EBNA1
 
 
 
GA and incubated for 14–16 h at 37
 
 
 
C. After incuba-
tion, cells were washed in growth medium, labeled with 
 
51
 
Cr for
60 min. After incubation, these cells were washed with growth
medium and used as targets in standard 5-h 
 
51
 
Cr-release assays
(25).
 
Results
 
EBNA1 Displays Differential Intracellular Stability in Differ-
ent Cell Types.
 
To determine the intracellular kinetics of
EBNA1 in different cell types, an EBV
 
  
 
B cell line (DG75)
and a number of epithelial cell lines (HEK293, HaCaT, and
SVMR6) were transiently transfected with expression vec-
tors pEGFP-N1, EBNA1-GFP, or EBNA1
 
 
 
GA-GFP, and
protein expression was analyzed by SDS-PAGE after incu-
bation with 50 
 
 
 
g/ml cycloheximide. The intensity of the
EBNA1-GFP band was measured by densitometric analy-
sis. Representative data from this analysis is shown in Fig. 1
B. Full-length EBNA1-GFP and GFP were highly stable in
DG75 cells and even after 30 h 
 
 
 
80% of the protein was
detectable. The stability of EBNA1 was also determined in
another B cell line (AS LCL) and also observed to have a
half-life of 
 
 
 
30 h (not depicted). In contrast, epithelial cells
transfected with EBNA1-GFP showed a rapid reduction in
EBNA1 levels with 
 
 
 
60% of the protein being degraded
within 24 h (Fig. 1 B). Densitometric analysis indicated
that the half-life for full-length EBNA1 in B cells was
 
 
 
30 h, whereas the half-life was as low as 
 
 
 
4 h in HaCaT
cells and 
 
 
 
20–24 h in SVMR6 and HEK293 cells (Fig. 1 
CD8
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C). Interestingly, the half-life of full-length EBNA1 versus
a truncated version of the antigen with GAr sequence de-
leted (EBNA1
 
 
 
GA) was quite comparable in the three ep-
ithelial cell lines tested, whereas there was a significant dif-
ference in the half-life of these proteins in B cells. Another
interesting feature of the EBNA1 expression observed in
epithelial cells was the presence of multiple low molecular
weight expression products, which may represent either
the degraded forms of the full-length protein or DRiPs. To
differentiate between DRiPs and postlysis artifacts, the ly-
sates from each time point were added to hot (95
 
 
 
C) sam-
ple buffer (2% SDS/1% 
 
  
 
mercaptoethanol/1% glycerol/65
mM Tris HCL, pH 6.5) and boiled for 10 min (26). These
samples were separated on 7.5% SDS-PAGE and displayed
a similar pattern of multiple low molecular weight expres-
sion products (not depicted). These results further support
our contention that these low molecular weight expression
products might be EBNA1 DRiPs. To demonstrate that
the expression of these recombinant proteins does not ef-
fect cell viability, the immunoblots were also probed with a
specific antibody to demonstrate the stability of actin over
the time course of the experiment. A similar pattern of sta-
ble actin expression was observed for all the transfectants
and demonstrated equal loading of lanes (not depicted).
To delineate the pathway for the rapid degradation of
EBNA1 in epithelial cells, we first tested the possibility that
this protein is targeted through the Ub-dependent path-
way. SVMR6 cells were transiently cotransfected with expres-
sion vectors encoding HA-tagged 8xUb and EBNA1-GFP,
EBNA1
 
 
 
GA-GFP, or LMP1-GFP. Previous studies have
shown that the EBV-LMP1 is degraded through the Ub/
proteasome-dependent pathway (27) and thus LMP1-GFP
was included as a positive control. 36 h after transfection,
these cells were lysed and Ub–EBNA1 or Ub–LMP1 com-
plexes were immunoprecipitated with an anti-HA–specific
mAb. These complexes were then resolved by SDS-PAGE,
followed by immunoblotting with a GFP-specific antibody.
Data presented in Fig. 2 A clearly shows that although
LMP1-GFP was ubiquitinated, no ubiquitination was ob-
served for EBNA1-GFP or EBNA1
 
 
 
GA-GFP. These re-
Figure 1. (A) Schematic description of EBNA1 and
EBNA1 GA expression constructs showing localiza-
tion of FLR and HPV epitopes. (B) Intracellular degra-
dation of EBNA1-GFP in different cell types. DG75 B
cells, HEK293 epithelial cells, SVMR6 keratinocytes,
and HaCaT keratinocytes were transfected with ex-
pression constructs EBNA1-GFP, EBNA1 GA-GFP,
or the control plasmid pEGFP-N1. At 36 h after trans-
fection, the cells were degraded over a 30-h time
course in the presence of 50  g/ml cycloheximide as
described in Materials and Methods. Molecular weight
standards are indicated at the side of each panel. (C)
Densitometric analysis of EBNA1-GFP, EBNA1 GA-
GFP, and GFP expression. Band intensities were quan-
tified by analysis of the imaging data and plotted as a
relative percentage of the signal at time 0 for EBNA1-
GFP, EBNA1 GA-GFP, and GFP.Tellam et al.  1425
sults are supported by recent studies by Holowaty et al. (28)
who showed that EBNA1 interacts with a Ub-specific pro-
tease, HAUSP/USP7, which is demonstrated to deubiquiti-
nate EBNA1. Furthermore, the pattern of intracellular deg-
radation of EBNA1 in epithelial cells remained unaffected
even after the addition of the proteasome inhibitor, lactacys-
tin. This was not the case when the same concentration of
lactacystin (10  M) was used to inhibit proteasome-depen-
dent degradation of another EBV protein, LMP1 (Fig. 2 B).
Surprisingly, these inhibitory effects do not prevent EBNA1
degradation in epithelial cells, suggesting that the rapid deg-
radation of EBNA1 in epithelial cells does not proceed
through the classical Ub/proteasome-dependent pathway.
Endogenous Processing of CTL Epitopes from EBNA1 in
EBV-infected B Cells. Previous studies have demonstrated
high frequencies of T cells in the peripheral circulation of
HLA B35  EBV-exposed individuals that recognize the
EBNA1-derived CTL epitope HPV (13). These T cells can
be readily expanded in vitro by stimulation with autolo-
gous LCLs. Blake et al. (14) proposed that this in vivo and
in vitro stimulation of T cells proceeds through the cross-
presentation of exogenous EBNA1 antigen, rather than di-
rect stimulation by the EBV-infected B cells.
To delineate the possible mechanisms involved in the in-
duction of EBNA1-specific T cell responses, PBMCs from
four HLA B*3501  EBV-exposed individuals (MW, CS,
TK, and TC) were stimulated with either B*3501  or
B*3501  LCLs to generate CTL cultures that were then
tested for reactivity with the HPV epitope. These stimula-
tor cells included the autologous LCLs, an HLA-mis-
matched LCL, the class I  LCL 721.221, or the 721.221
cell line that had been transfected with the HLA B*3501
gene. In all cases, the HLA B*3501  stimulator cells were
shown to be highly efficient at stimulating EBNA1-specific
CTLs, whereas the CTL cultures stimulated with B*3501 
cell lines showed negligible peptide-specific cytotoxicity
(Fig. 3). This stimulation of an HPV-specific memory re-
sponse was clearly dependent on the expression of TAP in
the stimulator cells as TAP 1– and TAP 2–deficient T2
Figure 2. Ubiquitination analysis of EBNA1-GFP
and EBNA1 GA-GFP in vitro. (A) SVMR6 kerati-
nocytes were transiently cotransfected with expression
vectors encoding HA-tagged 8xUb and LMP1-GFP,
EBNA1-GFP, or EBNA1 GA-GFP. Ubiquitinated
complexes were immunoprecipitated with an anti-
HA–specific mAb and immunoblotted with anti-GFP.
The ubiquitinated LMP1  control is indicated. (B) Ef-
fect of the proteasomal inhibitor lactacystin on the sta-
bility of EBNA1-GFP and LMP1-GFP in epithelial
cells. Duplicate aliquots of HaCaT cells were trans-
fected with the expression construct EBNA1-GFP or
LMP1-GFP. At 36 h after transfection, the proteasome
inhibitor lactacystin was added at a final concentration
of 10  g/ml for 12 h to one of the duplicates. Both
duplicates were then subjected to treatment with 50
 g/ml cycloheximide over a 6–8-h time course. Cell
lysates at the indicated time points were separated by
SDS-PAGE for immunoblotting with a GFP-specific
antibody. The absence ( ) or presence ( ) of lactacys-
tin is indicated. Densitometric analysis of the EBNA1-
GFP, LMP1-GFP, EBNA1-GFP plus lactacystin, and
LMP1-GFP plus lactacystin expression products are
shown.
Figure 3. Direct stimulation of EBNA1-specific CTL responses in
vitro using LCL stimulators. CTL bulk cultures were generated from the
HLA B*3501  EBV-seropositive donors MW, CS, TK, and TC by incu-
bating PBMCs with irradiated LCLs (responder/stimulator ratio of 20:1).
CTL cultures were split and restimulated with additional irradiated LCLs
on day 7. Stimulator cells were the class I  LCL 721.221, HLA B*3501-
transfected 721.221 cells, the autologous LCL for each donor, or an LCL
from the B*3501  donor DM. CTL cultures were also generated from
donor TK after stimulation with the T2 cell line or B*3501-transfected
T2 cells. On day 10, each CTL bulk culture was screened in chromium
release assays for lysis of HLA B*3501  PHA blasts that had been pre-
treated with 1  M of the HPV peptide for 1 h or left untreated. An E/T
ratio of 20:1 was used in each of these assays. These data are a representa-
tion of two separate experiments.CD8  T Cell Recognition of EBNA1 1426
cells transfected with B*3501 were unable to stimulate a
significant HPV-specific response (Fig. 3 C). These data
suggest that the HPV-specific T cell response can be di-
rectly activated by EBV-infected B cells and this EBNA1
epitope is efficiently processed through the TAP-depen-
dent pathway.
To further confirm these observations, we established an
ex vivo stimulation assay, in which PBMCs from three un-
related HLA B35–seropositive individuals were stimulated
with autologous LCLs, 721.221 LCL, 721.221 LCL trans-
fected with HLA B*3501 (referred to as 0.221.B*3501
LCL), or HLA B35  LCLs. After overnight incubation,
these cells were assessed for binding to an HPV-HLA
B*3501 tetramer and intracellular IFN-  expression. Data
presented in Fig. 4 clearly demonstrate that a large propor-
tion of HPV-HLA B*3501 tetramer  T cells showed strong
intracellular IFN-  expression after stimulation with autol-
ogous LCL or the 0.221.B*3501 LCL. On the other hand,
no ex vivo IFN-  response was observed within the HPV
tetramer  cells when the PBMCs were stimulated with the
HLA B35  LCLs or left unstimulated. A similar pattern of
IFN-  response was also observed in other donors when
stimulated with HLA B35  LCLs (not depicted) These ob-
servations further confirm our conclusions drawn from Fig.
3, which indicated that EBV-infected B cells can endoge-
nously process and present CTL epitopes directly to the vi-
rus-specific T cells.
In the next set of experiments, we further assessed the
endogenous processing of EBNA1 CTL epitopes by differ-
ent cell types using in vitro cytotoxicity assays. In the first
instance, we used a CTL clone(s) specific for the HLA
B35–binding HPV epitope to assess CTL lysis of B cells ex-
pressing EBNA1. Blake et al. (13) have previously shown
that T cells specific for this epitope are unable to recognize
HLA-matched EBV-transformed LCLs. Contrary to these
observations, we found that HPV-specific CTL clones do
recognize HLA B35  LCLs (Fig. 5 A), although there was
some degree of variation in the level of CTL lysis amongst
different HLA B35  LCLs. It is important to mention here
that the level of lysis observed for EBNA1-specific CTLs is
quite comparable to that seen for CTL clones specific for
other latent antigens (EBNA2-6; references 5 and 23). The
fine specificity of this CTL recognition was further con-
firmed by the recognition of 721.221 LCLs transfected
with HLA B35 (referred to as 0.221.B35 LCL), whereas no
CTL lysis was observed for 721.221 LCLs or other LCLs
that were negative for HLA B35 (Fig. 5, A and B). We
have also demonstrated that the endogenous presentation
of the HPV epitope was clearly dependent on the expres-
sion of TAP as T2 cells expressing HLA B35 were not rec-
ognized by these CTL clones (Fig. 5 B). In addition, the
killing of HLA B35 LCLs was completely blocked by the
pretreatment of these cells with BFA (not depicted). Taken
together, these results suggest that in spite of the highly sta-
ble expression of EBNA1 in B cells, CTL epitopes within
this protein can be directly presented by EBV-transformed
LCLs, and this presentation proceeds through a TAP-
dependent pathway.
Figure 4. Ex vivo intracellular IFN-  production by EBNA1-specific
T cells after stimulation with LCLs. PBMCs from an HLA B35  donor
were incubated alone (A) or with autologous LCL (B), 0.221.B35 LCL
(C), HLA B35  LCL (D), or 0.221 LCL (E). Samples shown were gated
on the CD8  population, and then the percentage of CD8  and HPV
tetramer  cells that were producing IFN-  was assessed. The percentage
of HPV-specific T cells producing IFN-  after LCL stimulation is shown
on the top right hand corner of each of the panels. These data are a repre-
sentation of two separate experiments.
Figure 5. CTL recognition of endogenously pro-
cessed EBNA1 epitopes. (A) HLA B35  and HLA
B35  LCLs were used as targets in a standard 51Cr-
release assay to assess endogenous processing of EBNA1.
(A) A CTL clone specific for the HLA B35-binding
HPVGEADYFEY epitope was added to target cells at
the E/T ratios indicated. (B) An HLA B35  LCL,
721.221 LCLs, 721.221 LCLs transfected with HLA
B*3501, T2 LCLs, and T2 LCLs transfected with HLA
B*3501 were used as targets in a standard 51Cr-release
assay to assess CTL activity to an HPVGEADYFEY-
specific CTL clone at an E/T ratio of 5:1. These data
are a representation of three separate experiments.Tellam et al.  1427
Although data presented in Fig. 5 clearly showed that
EBNA1 epitopes can be endogenously processed through
the class I pathway, it was important to further con-
firm these observations by using another human class
I–restricted epitope. To address this issue, we tested the
endogenous presentation of an inserted HLA B8–restricted
CTL epitope, FLRGRAYGL (referred to as FLR), from an
EBV-encoded EBNA3 protein within the EBNA1 COOH-
terminal sequence (referred to as EBNA1-FLR), which
allowed the study of endogenous processing of EBNA1
using an FLR-specific human CTL clone (11). The tar-
get cells were either transfected with expression vectors
(EBNA1-FLR-GFP or EBNA1 GA-FLR-GFP) or in-
fected with adenovirus encoding full-length EBNA1-FLR
protein. It should be noted that target LCLs used in these
assays were transformed with the B95.8 strain of EBV,
which carries a mutation within the FLR epitope (29). As
in the case of the HPV epitope, data presented in Fig. 6
shows that this epitope was endogenously processed by
some HLA B8  cells (AS LCL and C1R.B8) expressing
EBNA1-FLR, whereas other HLA B8  cells (LC LCLs)
failed to present this epitope. The specificity of this recog-
nition was confirmed by the inhibition of CTL killing of
target cells coexpressing on HSV-1–encoded TAP inhibi-
tor ICP47 (Fig. 6 B). These observations further confirm
that CTL epitopes within EBNA1 can be endogenously
processed and directly presented to CD8  T cells through a
TAP-dependent pathway.
Endogenous Processing of EBNA1 CTL Epitopes in Epi-
thelial Cells. Our intracellular kinetic studies had shown
that the EBNA1 protein was highly unstable in epithelial
cells. To test the hypothesis that the rapid degradation of
EBNA1 in these cells may enhance CTL recognition in
vitro, SVMR6 cells were infected with a recombinant
adenovirus expressing either full-length EBNA1-FLR or
EBNA1 GA-FLR, and then exposed to the CTL clone
(LC13) specific for the FLR epitope. Cells infected with
these recombinant adenoviruses showed similar levels of
protein expression (Fig. 7 A, inset). The data presented
in Fig. 7 A shows that SVMR6 cells expressing either
full-length EBNA1-FLR or EBNA1 GA-FLR were effi-
ciently recognized by an LC13 CTL clone and the level of
lysis was comparable to that seen in LCLs expressing
EBNA1 constructs (Fig. 6). As with the endogenous pro-
cessing of the EBNA1 epitopes in B cells, the CTL lysis of
SVMR6 cells was also blocked in the presence of BFA.
However, in contrast to the degradation of full-length
EBNA1, the presentation of the FLR CTL epitope in
SVMR6 cells was blocked by the proteasome inhibi-
tors, lactacystin and Cbz-L3 (Fig. 7 B). These observations
strongly suggest that the full-length EBNA1 protein is un-
likely to be the primary source of endogenously processed
epitopes. We hypothesize that EBNA1 CTL epitopes are
primarily derived from DRiPs and this presentation is de-
pendent on the proteasomal pathway. The endogenous
presentation of the FLR epitope within EBNA1 was not
affected by the addition of chloroquine or pepstatin. Unex-
pectedly, pretreatment of target cells with leupeptin signifi-
cantly enhanced the CTL recognition of the FLR epitope
within the COOH terminus of EBNA1 (Fig. 7 B). This in-
crease in CTL lysis was not observed when leupeptin-
treated target cells were presensitized with synthetic FLR
peptide (not depicted). To determine whether this en-
hanced killing of target cells after leupeptin treatment oc-
curred for another EBNA1 epitope, HLA B*3501-trans-
fected SVMR6 cells and LCLs were infected with AdEBNA1
and then exposed to the HPV-specific CTL clone, DY1.
Data presented in Fig. 7 C shows that leupeptin treatment
of these cells had no effect on the CTL recognition by an
HPV-specific CTL clone.
Newly Synthesized Protein Provides the Primary Source of
Endogenously Processed CD8  Epitopes from EBNA1. To
determine whether the endogenously processed epitopes
are derived from newly synthesized protein or from the
long-lived stable EBNA1, we used the ex vivo stimulation
assay in which PBMCs from an HLA B*3501  EBV-sero-
positive individual (MW) were stimulated with MHC–pep-
tide-stripped B*3501  LCLs that had been incubated in the
presence or absence of cycloheximide to block fresh pro-
tein synthesis. After overnight incubation, these cells were
Figure 6. Endogenous processing of an inserted
HLA B8–restricted CTL epitope within EBNA1. (A)
Two HLA B8  LCLs and the same LCLs transfected
with either the EBNA1-FLR-GFP or EBNA1 GA-
FLR-GFP expression constructs were used as targets in
a standard 51Cr-release assay to assess CTL activity to a
B8-specific CTL clone, LC13. An E/T ratio of 5:1 was
used in this assay. (B) C1R.B8 LCLs, C1R.B8.ICP47
LCLs, and the same LCLs infected with a recombinant
adenovirus encoding full-length EBNA1 (Ad-EBNA1-
FLR) were used as targets in a standard 51Cr-release as-
say to assess CTL activity. An HLA B8–restricted
FLR-specific CTL clone, LC13, was used as an effec-
tor in this assay. An E/T ratio of 5:1 was used in this
assay. These data are a representation of two separate
experiments.CD8  T Cell Recognition of EBNA1 1428
assessed for binding to an HPV HLA B*3501 tetramer and
for intracellular IFN-  expression. Data presented in Fig.
8 A demonstrate that  50% of HPV HLA B*3501
tetramer  T cells showed strong intracellular IFN-  ex-
pression after stimulation with untreated HLA B*3501 
LCLs. However, pretreatment of the LCLs with citrate
buffer followed by incubation with cycloheximide signifi-
cantly reduced the proportion of intracellular IFN- –
expressing T cells within the HPV HLA B*3501 tetramer 
population (18%). On the other hand, LCLs treated with
either citrate buffer (34.3%) or cycloheximide (53.1%)
alone had a less significant effect on the stimulating capa-
bility of these cells. This data is consistent with the levels
of surface MHC class I expression on LCLs after each of
these treatments (Fig. 8 B). Furthermore, stimulation of
PBMCs with PHA in the presence or absence of cyclo-
heximide and/or citrate buffer showed comparable levels
of IFN-  expression (not depicted). These observations
indicate that endogenously processed EBNA1 epitopes,
which stimulate antigen-specific T cells, are primarily de-
rived from newly synthesized protein rather than the
long-lived stable EBNA1.
Discussion
This work provides a new perspective on the T cell rec-
ognition of EBNA1 and raises important questions on the
current models to explain EBV persistence and the out-
growth of EBV-associated malignancies. A number of pre-
vious studies have proposed that EBV maintains latent in-
fection of host cells by restricting its gene expression to a
single protein, EBNA1 (30). This protein includes a unique
GAr sequence that is thought to protect these virus-
infected cells from immune recognition. The GAr sequence
has a cis-inhibitory effect on its own degradation and
blocks synthesis of EBNA1 protein in vitro and in vivo (8,
12). In spite of these inhibitory mechanisms, ex vivo analy-
sis of EBV-specific T cell responses revealed that not only
could EBNA1-specific T cells be readily detected, but in
some individuals these responses constituted a major com-
ponent of the EBV-specific T cell memory response (13,
14). The precursor frequency for these T cells was in the
same range as that seen for epitopes within the immu-
nodominant EBNA3 proteins (14). Because these EBNA1-
specific CTLs showed no direct recognition of EBV-
infected B cells, Blake et al. (13, 14) proposed that much of
Figure 7. Endogenous processing of EBNA1 CTL
epitopes in epithelial cells and the effect of MHC class I
and II inhibitors on endogenous processing of EBNA1
epitopes. (A) SVMR6 cells were infected with a re-
combinant adenovirus expressing either full-length
EBNA1-FLR or EBNA1 GA-FLR. These cells were
used as targets in a standard 51Cr-release assay to assess
endogenous processing of an HLA B8–restricted FLR
epitope encoded within EBNA1. The FLR-specific
CTL clone LC13 was used as effector cells in the assay.
An E/T ratio of 5:1 was used in the assay. The inset gel
photo shows relative expression levels of full-length
AdEBNA1 and AdEBNA1 GA after infection of
SVMR6 cells. (B) SVMR6 keratinocytes were pre-
treated with either class I inhibitors, 10  g/ml lactacys-
tin, 1  g/ml BFA, and 10  g/ml Cbz-L3, or class II
inhibitors, 80  M chloroquine, 100  M leupeptin,
and 50  M pepstatin, for 45 min. The cells were then
infected with a recombinant adenovirus expressing
full-length EBNA1 (Ad EBNA1-FLR). At 18 h after
infection, the cells were used as targets in a standard
51Cr-release assay to assess endogenous presentation of
the FLR epitope. FLR-specific CTL clone LC13 was
used as effector cells in the assay. An E/T ratio of 5:1
was used in the assay. This data is a representation of
three separate experiments. (C) CTL recognition of
EBNA1-expressing SVMR6 cells and LCLs (HLA
B35 , MW LCL; or HLA B35 , AS LCL) by HLA
B35–restricted HPV-specific CTL clone (DY1).
SVMR6 cells were transfected with an expression vec-
tor encoding the HLA B*3501 allele. Target cells were
either pretreated with 100  M leupeptin or left un-
treated. An E/T ratio of 5:1 was used in the assay.Tellam et al.  1429
this antigen-specific memory response is generated through
the cross-presentation of this antigen through a TAP-inde-
pendent pathway. However, data presented in this work
suggest that EBNA1 epitopes can be directly presented by
EBV-infected B cells through a proteasome/TAP-depen-
dent pathway.
An interesting feature of this observation was that the
endogenous presentation of the EBNA1 CTL epitope ap-
pears to be independent of the intracellular stability of this
antigen. In spite of the highly stable expression of EBNA1
in B cells, the level of CTL lysis of these cells was quite
comparable to that of epithelial cells, which showed less
stable expression of EBNA1. Surprisingly, the rapid degra-
dation of EBNA1 in epithelial cells appears to proceed
through a proteasome-independent pathway, whereas the
endogenous presentation of CTL epitopes within this pro-
tein was blocked in the presence of proteasome-specific in-
hibitors. This unexpected finding raised an important ques-
tion on the source of endogenously processed EBNA1
epitopes. Recent studies have proposed a novel source of
peptides associated with MHC class I molecules. These
peptides are mainly derived from DRiPs, which were re-
ferred to as “unavoidable imperfections in the process of
translating genetic information into functional proteins”
(17). There is increasing evidence to suggest that DRiPs
can account for a large fraction ( 30%) of newly synthe-
sized proteins that are rapidly degraded by proteasomes (16,
31). The data presented in this work is consistent with the
hypothesis that the primary source of endogenously pro-
cessed EBNA1 epitopes is derived from newly synthesized
protein rather than the long-lived stable EBNA1. Indeed,
the treatment of EBV-transformed LCLs with citrate buffer
and cycloheximide, which blocked the endogenous pre-
sentation of epitopes from newly synthesized EBNA1, sig-
nificantly impaired the stimulation of antigen-specific T
cells.
Further support for this hypothesis comes from an unex-
pected observation that the endogenous presentation of at
least one of the epitopes (FLR) within EBNA1 was en-
hanced after the addition of a cysteine protease inhibitor
(leupeptin). Yewdell et al. (17) have recently proposed that
after the degradation of DRiPs by proteasomes, peptides of
various lengths are produced and many of these peptides
are substrates for various cytosolic peptidases that further
degrade these peptides into single amino acids that are re-
cycled for the synthesis of new proteins. Thus, it is possible
that pretreatment of target cells with leupeptin inhibits cys-
teine proteases that either specifically cleave the FLR
epitope sequence alone or the DRiPs that include this
epitope from the extreme COOH-terminal region of
EBNA1. This argument is also supported by previous stud-
ies showing that endogenous processing of some MHC
Figure 8. (A) Effect of MHC–peptide stripping and
cycloheximide treatment on ex vivo intracellular IFN- 
production by EBNA1-specific T cells. PBMCs from
an HLA B35  donor were incubated alone or with ei-
ther an HLA B*3501  LCL, an HLA B*3501  LCL
plus 0.01  M HPV peptide, an HLA B*3501  LCL
treated with citrate buffer and 50  M cycloheximide,
an HLA B*3501  LCL treated with citrate buffer, or an
HLA LHLA B*3501  LCL treated with cyclohexi-
mide. Data shown represents the CD8  and tetramer 
population (solid bars) and the tetramer  population
producing IFN-  (shaded bars). This data is a represen-
tation of two separate experiments. (B) Surface MHC
class I expression on untreated LCLs or LCLs treated
with either cycloheximide, citrate buffer alone, or cy-
cloheximide and citrate buffer. LCLs were initially in-
cubated with MHC class I–specific mAb (W6/32) fol-
lowed by incubation with FITC-labeled anti–mouse
Ig. The fluorescence intensity was measured by FACS-
Calibur™ and data were analyzed by CELLQuest™
software. The results are expressed as mean fluores-
cence intensity.CD8  T Cell Recognition of EBNA1 1430
class I epitopes can be influenced by both proteasomes and
cysteine proteases (32).
It is important to mention here that in contrast to other
proteins, most of the endogenously processed CTL epi-
topes from EBNA1 might be derived from DRiPs be-
cause the GAr sequence within EBNA1 blocks proteaso-
mal degradation. Because many of these DRiPs may not
include GAr sequences, the presentation of CTL epitopes
from DRiPs proceeds through a classic TAP/proteasome-
dependent pathway. Indeed, data presented in this work
and previous studies published by Blake et al. have shown
that expression of full-length EBNA1 either by vaccinia
(13) or adenovirus (Fig. 7, inset) results in the expression of
GAr-deleted truncated products, which is consistent with
the presence of DRiPs. Furthermore, this view is compati-
ble with recent findings that other EBNA1 epitopes are
processed independent of their location relative to the GAr
domain (33, 34).
The demonstration of endogenous processing of EBNA1
and the lysis of EBV-transformed LCLs by EBNA1-specific
CTLs needs to be addressed in the context of previous ob-
servations that suggested that this protein escapes T cell
recognition by inhibiting its proteasomal degradation. One
possible reason for the discrepancy relates to the difficulty
of isolating EBNA1-specific CTLs using EBV-transformed
LCLs as stimulators that are known to selectively expand T
cells specific for immunodominant EBNA3 family proteins.
However, the use of overlapping peptides from EBNA1 to
stimulate T cells in vitro, and newer and more sensitive
technologies to assess immune responses, have facilitated
opportunities to not only map EBNA1 epitopes, but also
to investigate the issue of the endogenous processing of
EBNA1. Although the data presented in this work is con-
sistent with the previous biochemical observations that the
GAr domain inhibits degradation of the full-length EBNA1
protein in B cells (9), this inhibitory effect is not absolute in
blocking CD8   CTL recognition of EBV-transformed
LCLs.
Overall, this work has important implications for the im-
mune control of EBV-associated diseases. First, these ob-
servations provide a new opportunity for the development
of novel therapeutic strategies against EBV-associated ma-
lignancies. Although much of the emphasis on the de-
velopment of therapeutic vaccines for EBV-associated
nasopharyngeal carcinoma and Hodgkin’s disease have pri-
marily concentrated on latent membrane antigens 1 and 2,
inclusion of EBNA1 epitopes may significantly enhance
their therapeutic potential. These studies also open the
possibility of targeting Burkitt lymphoma cells through
EBNA1, although the loss of TAP expression in these ma-
lignant cells remains a major hindering factor. The second
important implication relates to the latent infection of EBV
in healthy virus carriers. Previous studies have proposed
that because EBNA1 is required to maintain the viral ge-
nome, latently infected B cells restrict viral gene expression
to EBNA1 only, thus limiting immune recognition by T
cells. This assumption was based on the observations that T
cell epitopes from EBNA1 are not endogenously processed
and presented by EBV-infected B cells. However, the data
presented in this work has raised questions on the relevance
of this hypothesis. In a recent study, Hochberg et al. (35)
have shown that most of the EBV-infected B cells in the
blood do not express any detectable latent antigen mRNA
or proteins. However, when these infected cells divide,
they express EBNA1 only. These EBNA1-expressing di-
viding B cells might be controlled by EBNA1-specific T
cells, whereas a long-term latent infection is maintained by
completely switching off the expression of all EBV-latent
genes.
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